Edwards Lifesciences Corp (EW)

Financial leverage ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Total assets	US$ in thousands	13,055,300	12,971,200	10,099,300	9,736,300	9,363,200	9,370,800	9,004,000	8,651,200	8,292,500	8,638,200	8,425,100	8,419,900	8,502,600	8,160,300	7,662,100	7,213,700	7,237,100	6,800,800	6,424,100	6,076,100
Total stockholders’ equity	US$ in thousands	9,998,400	9,545,600	7,437,400	7,117,900	6,650,000	6,657,500	6,375,700	5,978,000	5,806,700	6,217,800	5,943,600	5,844,900	5,835,900	5,541,300	5,133,300	4,658,400	4,574,300	4,210,300	3,839,100	3,901,100
Financial leverage ratio		1.31	1.36	1.36	1.37	1.41	1.41	1.41	1.45	1.43	1.39	1.42	1.44	1.46	1.47	1.49	1.55	1.58	1.62	1.67	1.56

December 31, 2024 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $13,055,300K ÷ $9,998,400K
= 1.31

The financial leverage ratio of Edwards Lifesciences Corp has been gradually decreasing from 1.56 as of March 31, 2020, to 1.31 as of December 31, 2024. This indicates that the company's reliance on debt is reducing relative to its equity over the period under review. A lower financial leverage ratio suggests a stronger equity position and lower financial risk for the company. It appears that Edwards Lifesciences Corp has been effectively managing its debt levels and improving its capital structure over the years. This trend is positive as it signifies a healthier balance between debt and equity in the company's capital structure.